A Comparison of Stereotactic Radiation Therapy in Elderly Patients with Central or Peripheral Stage I-II (T1-3 N0 M0) Non-Small Cell Lung Cancer
Authors:
Open Access
- 1 November 2024
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 16, 1557-1570
Abstract
Purpose: The objective of this study was to compare the clinical outcomes of stereotactic body radiation therapy (SBRT) in elderly patients aged 65 or older with clinical stage I–II non-small-cell lung cancer (NSCLC), specifically examining the differences between centrally located lung tumors and peripherally located lung tumors. Methods: From April 2009 to January 2020, a total of 136 patients with 136 tumors (65 central, 71 peripheral; NSCLC) at an early stage (T1-3N0M0) were treated with SBRT at a single institution. Central/peripheral location was assessed retrospectively on planning CT scans. A propensity score matching analysis was utilized to compare the two groups. In addition, the prognosis and related toxicity were compared between the two study arms. Results: A total of 33 central tumors and 33 peripheral tumors were matched and analyzed. The results showed no significant differences in overall survival (OS) and progression-free survival (PFS) between the two groups. The 2-year OS was 71.88% (95% CI, 57.87%-89.27%) in the central lung cancer group, while it was 93.94% (95% CI, 86.14%-100.00%) in the peripheral lung cancer group (P=0.462). The 2-year PFS was 43.75% in the central lung cancer group, while it was 78.79% in the peripheral lung cancer group (P=0.279). Further subgroup analysis indicated that the location of peripheral tumor have a positive impact on OS in patients with adenocarcinoma. The occurrence of local failure, regional failure, or distant failure was comparable between central and peripheral tumors. There was no statistically significant difference in toxicity between the central and the peripheral tumor groups. Conclusion: The outcomes of SBRT for central tumors versus peripheral lung tumors in elderly patients with early-stage NSCLC were similar. SBRT demonstrated a similar level of safety in terms of toxicity for both central and peripheral lung tumors.Keywords
This publication has 35 references indexed in Scilit:
- Screening Tools for Identifying Older Adults With Cancer Who May Benefit From a Geriatric AssessmentJAMA Oncology, 2021
- The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patientsJournal of Cancer Research and Clinical Oncology, 2019
- Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experienceLa radiologia medica, 2018
- SBRT for Central Tumors in Early Stage NSCLC PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Surgery or stereotactic body radiotherapy for elderly stage I lung cancer? A propensity score matching analysisSurgery Today, 2017
- Place du gériatre dans la prise en charge des patients âgés atteints de cancerCancer/Radiothérapie, 2015
- Toxicity After Central versus Peripheral Lung Stereotactic Body Radiation Therapy: A Propensity Score Matched-Pair AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Local Control and Toxicity in a Large Cohort of Central Lung Tumors Treated With Stereotactic Body Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer: How to Fly in a “No Fly Zone”International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Prospective, Risk-Adapted Strategy of Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer: Results of a Phase II TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011